TG Therapeutics (TGTX) Tops Q3 EPS by $2.21, Beats on Revenue; Offers Guidance

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of $2.43, $2.21 better than the analyst estimate of $0.22. Revenue for the quarter came in at $161.7 million versus the consensus estimate of $152.23 million.

2025 Financial Guidance

Raises BRIUMVI U.S. net product revenue target to approximately $585 million for the full year 2025 (prior guidance of $570 - $575 million for full year 2025)
Raises total global revenue target to approximately $600 million for the full year 2025 (prior guidance of $585 million for full year 2025)

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Tenax Therapeutics (TENX) PT Raised at Piper Sandler: 'Here's Why Now Is The Time to Own'
• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO